Skip to main content
Ernexa Therapeutics Inc. logo

Ernexa Therapeutics Inc. — Investor Relations & Filings

Ticker · ERNA ISIN · US6294106066 US Manufacturing
Open in API
Filings indexed 1,027 across all filing types
Latest filing 2024-03-22 Delisting Announcement
Country US United States of America
Listing US ERNA

About Ernexa Therapeutics Inc.

https://www.ernexatx.com/

Ernexa Therapeutics Inc. is a biopharmaceutical company developing cell therapies for advanced cancer and autoimmune diseases. The company's core technology platform engineers induced pluripotent stem cells (iPSCs) and differentiates them into induced mesenchymal stem cells (iMSCs). These engineered iMSCs are designed as scalable, off-the-shelf treatments that leverage the natural ability of MSCs to home to sites of tumors or inflammation. Once at the target site, the cells deliver therapeutic payloads, such as cytokines, to modulate the immune system. The company's lead candidate, ERNA-101, is being developed for the treatment of ovarian cancer. Its pipeline also includes ERNA-201, a cell therapy designed to target inflammation in autoimmune diseases.

Recent filings

Filing Released Lang Actions
8-K
Delisting Announcement Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 19, 2024, by Eterna Therapeutics Inc. It reports receipt of a notice from Nasdaq regarding non-compliance with a listing rule due to stockholders' equity being below the required threshold. The document discusses the company's plan to regain compliance and the potential consequences of failing to do so, including delisting. The content is a formal announcement about the company's listing status and compliance issues, specifically a notice of potential delisting. It does not contain financial statements or detailed financial analysis, nor is it a report publication or certification. Therefore, it fits the category of a Delisting Announcement (DLST). The document length is 3772 characters, which is consistent with a detailed announcement rather than a brief notice or a full report.
2024-03-22 English
10-K/A
Annual Report FY 2023
2024-03-18 English
10-K
Annual Report FY 2023
2024-03-14 English
FORM 3
Director's Dealing
2024-02-16 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated February 12, 2024, reporting the appointment of a new director, Mr. Peter Cicala, to the Board of Directors of Eterna Therapeutics Inc. It details his committee assignments and confirms no related party transactions. The content focuses on changes in the company's board and management. There are no financial statements or earnings data, nor is it a report or announcement of a report publication. This fits the category of Board/Management Information (MANG). The document length is 4108 characters, which is consistent with a typical 8-K filing for management changes.
2024-02-16 English
SC 13G/A
Major Shareholding Notification
2024-01-31 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.